| Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. | |
| | |
MedLine Citation:
|
PMID: 17356927 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There is consensus that patients should be treated with antiplatelet agents, beta-blockers, ACE-inhibitors/ARBs, and lipid lowering drugs for secondary prevention after acute myocardial infarction (AMI), but this evidence-based pharmacotherapy is underutilized. A quality improvement program was conducted in the Austrian county of Burgenland to emphasize the importance of cardiovascular drug therapy at hospital discharge in patients with AMI. In this prospective cohort study 250 members of a regional health insurance company, Burgenländische Gebietskrankenkasse (BGKK), with AMI during the year 2003 were identified using BGKK database. Discharge prescriptions and pharmacy reimbursement data of all included patients were determined. Overall prescription rate for patients discharged from hospital after AMI (n = 207) was 86% for platelet aggregation inhibitors, 77% for ACE-inhibitors or ARBs, 72% for beta-blockers, and 68% for a lipid lowering agent including statins. The all-cause mortality rate during a mean follow-up period of 552 days was 20%. Hazard ratio (HR) for death of patients with maximum 2 medications vs. those receiving 3 or 4 medications was 2.23 (95% CI: 1.19-4.18; p = 0.012). These data demonstrate that use of evidence-based drug treatment for prevention of mortality in patients with AMI is associated with risk reduction and survival benefit. Continuous quality improvement initiatives serve to improve outcome after AMI. |
| | |
Authors:
|
Ghazaleh Gouya; Berthold Reichardt; Gerald Ohrenberger; Michael Wolzt |
Related Documents
:
|
16211207 - Carvedilol improves myocardial contractility compared with metoprolol in patients with ... 20889997 - Use of propranolol in infantile haemangioma among chinese children. 3903527 - Unilateral parenchymatous kidney disease and hypertension: results of nephrectomy and m... 12944027 - Treatment with amlodipine and atorvastatin have additive effect in improvement of arter... 19180727 - Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and casp... 18613777 - Comparison of photoselective vaporization of the prostate and transurethral resection o... |
Publication Detail:
|
Type: Journal Article Date: 2007-03-14 |
Journal Detail:
|
Title: European journal of epidemiology Volume: 22 ISSN: 0393-2990 ISO Abbreviation: Eur. J. Epidemiol. Publication Date: 2007 |
Date Detail:
|
Created Date: 2007-03-23 Completed Date: 2007-05-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8508062 Medline TA: Eur J Epidemiol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 145-9 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, Allgemeines Krankenhaus Wien, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Austria / epidemiology Cardiovascular Agents / administration & dosage, therapeutic use* Cohort Studies Drug Therapy, Combination Drug Utilization Evidence-Based Medicine Female Humans Male Middle Aged Myocardial Infarction / drug therapy*, mortality* Patient Discharge / statistics & numerical data* Quality Assurance, Health Care / organization & administration Survival Analysis |
| Chemical | |
Reg. No./Substance:
|
0/Cardiovascular Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belg...
Next Document: Molecular characterization of the full-length 23S and 5S ribosomal RNA (rRNA) genes of Taylorella as...